Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas Ward

Showing results (81-90 of 181) with videos related to

Pageof 19
Sort By:
Epidemiology and Infection|September 4, 2023
Understanding the leading indicators of hospital admissions from COVID-19 across successive waves in the UKJonathon Mellor, Christopher E Overton, Martyn Fyles, et al.
Journal of Vascular and Interventional Radiology : JVIR|November 3, 2015
Cost Accounting as a Tool for Increasing Cost Transparency in Selective Hepatic Transarterial ChemoembolizationOsman Ahmed, Mikin Patel, Thomas Ward, et al.
European Journal of Gastroenterology & Hepatology|November 7, 2015
The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UKPhil McEwan, Hayley Bennett, Thomas Ward, et al.
Materials Horizons|November 25, 2021
Passivation-driven speciation, dealloying and purificationAndrew Martin, Boyce Chang, Joel Cutinho, et al.
The Journal of Infection|March 7, 2025
Understanding the effectiveness of the Comirnaty monovalent and bivalent vaccines during the Winter Coronavirus (COVID-19) Infection StudyThomas Ward, Robert S Paton, Christopher E Overton, et al.
BMC Psychiatry|May 24, 2022
Participants' experiences of AVATAR therapy for distressing voices: a thematic qualitative evaluationMar Rus-Calafell, Nils Ehrbar, Thomas Ward, et al.
Journal of Comparative Effectiveness Research|June 5, 2018
Daclatasvir combined with asunaprevir is a cost-effective and cost-saving treatment for hepatitis C infection in ChinaWen Chen, Thomas Ward, Mai Ping Tan, et al.
Archives of Dermatology|December 22, 2010
Sporotrichoid Staphylococcus aureus infection in an immunosuppressed patientErick Jacobson-Dunlop, Rodd Takiguchi, Thomas Ward, et al.
Nature Communications|January 16, 2026
Estimating COVID-19 incidence and prevalence using lateral flow tests in England and Scotland, 2023-2024Martyn Fyles, Jonathon Mellor, Robert S Paton, et al.
Journal of Medical Economics|December 20, 2019
Cost-effectiveness of targeted screening for the identification of patients with atrial fibrillation: evaluation of a machine learning risk prediction algorithmNathan R Hill, Belinda Sandler, Ruth Mokgokong, et al.
Pageof 19

Showing results (81-90 of 181) with videos related to

Sort By:
Pageof 19
Epidemiology and Infection|September 4, 2023
Understanding the leading indicators of hospital admissions from COVID-19 across successive waves in the UKJonathon Mellor, Christopher E Overton, Martyn Fyles, et al.
Journal of Vascular and Interventional Radiology : JVIR|November 3, 2015
Cost Accounting as a Tool for Increasing Cost Transparency in Selective Hepatic Transarterial ChemoembolizationOsman Ahmed, Mikin Patel, Thomas Ward, et al.
European Journal of Gastroenterology & Hepatology|November 7, 2015
The cost-effectiveness of daclatasvir-based regimens for the treatment of hepatitis C virus genotypes 1 and 4 in the UKPhil McEwan, Hayley Bennett, Thomas Ward, et al.
Materials Horizons|November 25, 2021
Passivation-driven speciation, dealloying and purificationAndrew Martin, Boyce Chang, Joel Cutinho, et al.
The Journal of Infection|March 7, 2025
Understanding the effectiveness of the Comirnaty monovalent and bivalent vaccines during the Winter Coronavirus (COVID-19) Infection StudyThomas Ward, Robert S Paton, Christopher E Overton, et al.
BMC Psychiatry|May 24, 2022
Participants' experiences of AVATAR therapy for distressing voices: a thematic qualitative evaluationMar Rus-Calafell, Nils Ehrbar, Thomas Ward, et al.
Journal of Comparative Effectiveness Research|June 5, 2018
Daclatasvir combined with asunaprevir is a cost-effective and cost-saving treatment for hepatitis C infection in ChinaWen Chen, Thomas Ward, Mai Ping Tan, et al.
Archives of Dermatology|December 22, 2010
Sporotrichoid Staphylococcus aureus infection in an immunosuppressed patientErick Jacobson-Dunlop, Rodd Takiguchi, Thomas Ward, et al.
Nature Communications|January 16, 2026
Estimating COVID-19 incidence and prevalence using lateral flow tests in England and Scotland, 2023-2024Martyn Fyles, Jonathon Mellor, Robert S Paton, et al.
Journal of Medical Economics|December 20, 2019
Cost-effectiveness of targeted screening for the identification of patients with atrial fibrillation: evaluation of a machine learning risk prediction algorithmNathan R Hill, Belinda Sandler, Ruth Mokgokong, et al.
Pageof 19